We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Protein Identified Modifies Gene Expression in Response to Mitochondrial Damage

By LabMedica International staff writers
Posted on 03 Jan 2017
A protein has been identified that causes changes in cellular gene expression in response to stress or disease related impairment in mitochondrial function.

Reduced mitochondrial DNA copy number, mitochondrial DNA mutations or disruption of electron transfer chain complexes induce mitochondria-to-nucleus retrograde signaling, which induces global change in nuclear gene expression ultimately contributing to various human pathologies including cancer. More...
Recent studies suggested that these mitochondrial changes caused transcriptional reprogramming of nuclear genes although the mechanism of this cross talk was not clarified.

Investigators at the University of Pennsylvania (Philadelphia, USA) recently described a mechanism by which mitochondria could drive changes in nuclear gene expression that were associated with tumor progression. They reported in the December 6, 2016, online edition of the journal Cell Discovery that mitochondria-to-nucleus retrograde signaling regulated chromatin acetylation and altered nuclear gene expression through the activity of the protein hnRNAP2 (heterogeneous ribonucleoprotein A2).

To evaluate the role of hnRNPA2 in mitochondria-to-nucleus communication, the investigators traced its activity in cells with depleted levels of mitochondria. Results showed that hnRNPA2 activated gene promoters of stress-associated genes in the nucleus by binding to them. Furthermore, hnRNPA2 activated these genes by acetylating a histone, which loosened the tightly packed chromatin, allowing DNA transcription to proceed more readily. These processes were reversed when mitochondrial DNA content was restored to near normal cell levels.

These findings suggest an important role for mitochondria as determinants of cell fate by altering the expression of large sets of nuclear genes through epigenetic mechanisms.

"Our study provides a rigorous demonstration of a link between mitochondrial function and nuclear gene expression," said senior author Dr. Narayan Avadhani, professor of biochemistry at the University of Pennsylvania. "Since we know that this type of signaling has a direct role in the early stages of cancer progression, the protein involved could be a very valuable target for alleviating this signaling and possibly cancer progression."

Related Links:
University of Pennsylvania


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.